Nathan Connell: Why Prophylaxis in vWD Has Historically Lagged Behind Established Practice in Hemophilia
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on Linkedln about a recent article he and his colleagues co-authored, adding:
“I’m pleased to share our recent paper, ‘Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?’ published in Therapeutic Advances in Hematology.
It was a privilege to work on this with Robert Sidonio, Fernando Corrales-Medina, Jill Johnsen, Michelle Sholzberg, and Caroline Malcolmson.
In this review, we examine why prophylaxis in von Willebrand disease has historically lagged behind established practice in hemophilia, despite a substantial bleeding burden in patients with severe and recurrent disease.
We discuss barriers to broader implementation, review emerging clinical evidence supporting prophylactic VWF replacement, and argue that the field is moving toward a more individualized, phenotype-driven approach that may help bring VWD care closer to parity with hemophilia.
Recent prospective data and regulatory progress suggest that prophylaxis should be considered more systematically for appropriately selected patients.
Thank you to Octapharma for supporting the medical writing assistance for this publication.”
Title: Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?
Authors: Robert F. Sidonio Jr., Fernando F. Corrales-Medina, Jill M. Johnsen, Michelle Sholzberg, Caroline Malcolmson, Nathan T. Connell
Read the Full Article on Therapeutic Advances in Hematology
Other posts featuring Nathan Connell on Hemostasis Today.
-
Nov 4, 2026, 18:57Connecting Haemophilia Centres, Certifying Treaters, and Improving National Data in Romania – EHC
-
Nov 4, 2026, 18:45Smitirupa Mishra: A Practical Guide to Coagulation Pathway Assessment and Laboratory Interpretation
-
Nov 4, 2026, 15:59Alessandra Bosch: A Successful Patient Day for the Bleeding Disorders Community in Zürich
-
Nov 4, 2026, 15:47Wolfgang Miesbach: Targeting Hepatic Endothelial Cells for Lentiviral Gene Therapy in Haemophilia A
-
Nov 4, 2026, 15:20Augustina Isioma Ikusemoro: Before You Transfuse, Think PBM
-
Nov 4, 2026, 14:23Advancing Hemophilia Care Through Global Research – WFH
-
Nov 4, 2026, 14:12Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery
-
Nov 4, 2026, 13:59Rita Li: ASH 2026 Abstract Achievement Award for Gut Microbiome Research
-
Nov 4, 2026, 13:38Omid Seidizadeh: Improving Access to von Willebrand Disease Diagnosis and Treatment Across Europe